FGFR Blockade by Pemigatinib Treats Naïve and Castration Resistant Prostate Cancer

Investigators validated the therapeutic efficacy the FDA-approved FGFR inhibitor pemigatinib, in an integrated platform consisting of human and murine prostate cancer (PCa) cells, and the transgenic multistage TRAMP model of PCa that recapitulated both androgen-dependent and CRPC settings.